BIIB Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 10.87% compared to Biogen's net margin of 50.24%. Biogen's return on equity of 10.33% beat Johnson & Johnson's return on equity of 30.18%.

Biogen has a consensus price target of $190.50, signalling upside risk potential of 60.3%. On the other hand Johnson & Johnson has an analysts' consensus of $169.84 which suggests that it could grow by 9.87%. Given that Biogen has higher upside potential than Johnson & Johnson, analysts believe Biogen is more attractive than Johnson & Johnson.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.21% to investors and pays a quarterly dividend of $1.24 per share. Biogen pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.5B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Biogen's net income of $266.7M is lower than Johnson & Johnson's net income of $11B. Notably, Biogen's price-to-earnings ratio is 10.62x while Johnson & Johnson's PE ratio is 17.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.79x versus 4.20x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 10.87% compared to Biogen's net margin of 32.59%. Biogen's return on equity of 10.33% beat Eli Lilly and's return on equity of 80.24%.

Biogen has a consensus price target of $190.50, signalling upside risk potential of 60.3%. On the other hand Eli Lilly and has an analysts' consensus of $1,008.64 which suggests that it could grow by 14.03%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.61% to investors and pays a quarterly dividend of $1.50 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.5B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biogen's net income of $266.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Biogen's price-to-earnings ratio is 10.62x while Eli Lilly and's PE ratio is 75.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.79x versus 17.75x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 10.87% compared to Biogen's net margin of -117.16%. Biogen's return on equity of 10.33% beat Moderna's return on equity of -29.09%.

Biogen has a consensus price target of $190.50, signalling upside risk potential of 60.3%. On the other hand Moderna has an analysts' consensus of $49.96 which suggests that it could grow by 83.55%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Moderna quarterly revenues of $956M. Biogen's net income of $266.7M is higher than Moderna's net income of -$1.1B. Notably, Biogen's price-to-earnings ratio is 10.62x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.79x versus 3.30x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 10.87% compared to Biogen's net margin of -747.33%. Biogen's return on equity of 10.33% beat Sage Therapeutics's return on equity of -63.59%.

Biogen has a consensus price target of $190.50, signalling upside risk potential of 60.3%. On the other hand Sage Therapeutics has an analysts' consensus of $8.10 which suggests that it could grow by 4%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.304%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Biogen's net income of $266.7M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Biogen's price-to-earnings ratio is 10.62x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.79x versus 11.48x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.